Veru Inc.
VERU
|
$1.305
-8.1%
-8.81%
2.6M
|
Health Technology
(0.0% 1d) (140.7% 1m) (18.3% 1y) (0.0% 2d) (22.4% 3d) (-7.2% 7d) (179.09% volume)
Earnings Calendar: 2024-02-08
Market Cap: $ 191,027,448
http://www.verupharma.com
Sec Filling | Patents | 386 employees
(United States) Veru, Inc. is an oncology and urology biopharmaceutical company. It develops medicines for prostate cancer treatment and prostate cancer supportive care as well as urology specialty pharmaceuticals. Its oncology drug candidates includes VERU-111, an oral alpha and beta tubulin inhibitor, which is in a phase 1b/2 study for the treatment of metastatic castration resistant prostate cancer; Zuclomiphene citrate, which is in a phase 2 clinical trial for the treatment of hot flashes in men undergoing prostate cancer hormonal therapies; and VERU-100, a long-acting GnRH antagonist 3 month subcutaneous depot, planned phase 2 clinical trial for the treatment of hormone sensitive advanced prostate cancer. The company’s urology specialty pharmaceutical drug candidate is TADFIN, a tadalafil and finasteride combination oral capsule, for the treatment of men with benign prostatic hyperplasia. Its commercial products include the FC2 Female/Internal condom for prevention of pregnancy and sexually transmitted infections and PREBOOST 4% benzocaine wipes for the prevention of premature ejaculation marketed as Roman Swipes by getroman.com. The company was founded by William R. Gargiulo Jr. and O.B. Parrish in 1996 and is headquartered in Miami, FL.
prostate cancer cancer hormone pregnancy clinical trials treatment corea cancer treatments injection
Drugs
Intimate Wipe (benzocaine)add to watch list Paper trade email alert is off
Press-releases
Veru Announces Date of 2024 Annual Meeting of Shareholders
Published: 2024-04-01 (Crawled : 20:00) - globenewswire.com
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: 5.05%
H: 2.77%
C: 2.0%
meeting
Veru Reschedules Annual Meeting of Shareholders
Published: 2024-03-22 (Crawled : 20:00) - globenewswire.com
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
| Email alert
Add to watchlist
meeting
Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss
Published: 2024-03-12 (Crawled : 12:00) - globenewswire.com
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.21%
H: 0.11%
C: -1.06%
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.9%
H: 2.03%
C: 1.89%
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: -0.53%
H: 2.22%
C: -3.59%
ALT | $6.91 0.29% 0.29% 3.6M
|
Commercial Services
|
| O: 0.3%
H: 11.41%
C: 9.8%
medical program
Veru Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q
Published: 2024-02-28 (Crawled : 00:00) - globenewswire.com
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: -0.96%
H: 0.0%
C: -3.67%
nasdaq report
Veru Announces New Scientific Advisory Board for its Enobosarm Program for High Quality Weight Loss
Published: 2024-02-20 (Crawled : 13:30) - globenewswire.com
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: 3.35%
H: 7.0%
C: 0.82%
program
Veru Reports Fiscal 2024 First Quarter Financial Highlights
Published: 2024-02-08 (Crawled : 12:00) - globenewswire.com
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: -2.84%
H: 2.92%
C: -3.84%
first financial
Veru Announces FDA Clearance of IND Application to Initiate Phase 2b Clinical Trial with Enobosarm to Treat Muscle Loss Associated with Weight Loss Drugs
Published: 2024-02-06 (Crawled : 14:00) - globenewswire.com
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: -1.04%
H: 1.51%
C: -9.12%
fda treat clearance application trial
Veru to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Published: 2024-01-31 (Crawled : 13:30) - globenewswire.com
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: -0.3%
H: 8.83%
C: 4.08%
conference life sciences
Veru to Report Fiscal 2024 First Quarter Financial Results on February 8, 2024
Published: 2024-01-25 (Crawled : 13:30) - globenewswire.com
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: 2.28%
H: 4.38%
C: 1.08%
first report financial results
Veru Submits IND Application to FDA for the Development of Enobosarm to Prevent Muscle Loss While Augmenting Fat Loss in Combination with GLP-1 Drugs for Weight Loss
Published: 2024-01-08 (Crawled : 13:30) - globenewswire.com
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: -1.74%
H: 4.2%
C: -3.09%
fda application
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Last 48 Hours Insiders Buying
RKT | News P 380 | $11.68 1.3% 0.17% 1.9M
|
Finance
|
22:30
HROW | $10.43 -3.87% -4.03% 680K
|
Health Technology
|
22:30
BCDA | $0.377 -1.4% 97K
|
Health Technology
|
22:00
CLSD | $1.29 -2.27% -2.33% 230K
|
Health Technology
|
14:00
CDZI P 25000 | $2.25 0.0% 260K
|
Utilities
|
14:00
ETST P 39000 | $0.068 -67.14% 43K
|
Manufacturing
|
13:30
FNLC P 1275 | $22.97 3.66% 3.53% 21K
|
Finance
|
12:30
ADMQ | $0.0532 -40.18% 480K
|
|
10:30
AXR P 2400 | $21.0 -5.28% 0.0% 13K
|
Finance
|
21:00
QCRH P 118 | $57.315 3.44% 3.32% 66K
|
Finance
|
18:01
VUZI P 7500 | $1.19 -5.56% -5.88% 550K
|
Electronic Technology
|
18:00
RMCF | $3.67 3.38% 3.27% 11K
|
Consumer Non-Durables
|
20:10